Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP:BAYRY)

7.975 -0.245 (-2.98%)
Streaming Delayed Price Updated: 1:14 PM EDT, Sep 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Aktienges ADR

< Previous 1 2 3 4 5 6 7 Next >
Top Financial Stories Wednesday, September 14: Multiple Antitrust Setbacks For Google, Bitcoin Crashes, Visa Finds New Gun Control System Ineffective And More...
Reuters 
Via Benzinga
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report
 
Via Benzinga
BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs Standard Treatment In Solid Tumors
 
Via Benzinga
Deere Invests Billions In Self-Driving Tractors, Smart Crop Sprayers: Report
 
Via Benzinga
Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death
 
Via Benzinga
Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration
 
Via Benzinga
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
 
Via Benzinga
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
 
Via Benzinga
7 Stocks Under $15 to Buy and Hold Forever
For patient investors who are willing to absorb potential turbulence, these are the stocks under $15 to buy for the long haul. 
Via InvestorPlace
Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops
The companies hoped to reduce the risk of myriad complications for at-risk patients. 
Via Investor's Business Daily
This Biotech Says Stem Cells May Be Key To Freeing 65 Million Americans From Chronic Back Pain, Painkiller Dependence
BioRestorative Therapies Inc. (NASDAQ: BRTX), a stem cell-focused biotech, says it wants to shift the paradigm of how doctors treat chronic pain in hopes of giving patients an option that’s effective,... 
Via Benzinga
Why Is Ginkgo Bioworks (DNA) Stock in the Spotlight Today?
DNA stock is down even while Ginkgo Bioworks prepares to purchase a biotech business and a large research and development site. 
Via InvestorPlace
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
 
Via Benzinga
Science Wednesday: 'Silent Spring' At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages
(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.) 
Via Benzinga
BWXT Medical, Bayer Ink Commercial Agreement For Actinium-225 Based Products
 
Via Benzinga
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. 
Via Benzinga
7 Blue-Chip Stocks to Buy Now if You Have $250 to Spend
These seven blue-chip stocks are trading at relative bargains and they can all be added to your portfolio for less than $250. 
Via InvestorPlace
Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off
 
Via Benzinga
Three Stocks To Buy In This Bear Market
There’s a silver lining to the current bear market. It’s created great buying opportunities. 
Via Talk Markets
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
 
Via Benzinga
How Heart Drugs Could Pump $10 Billion Into Merck's Coffers
As Keytruda's patent protection looms, will Merck be able to stanch the sales losses? 
Via Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
22nd Century Group Reports Q1 Net Sales Of $9M, Up 33% YoY, Net Loss Also Grows
22nd Century Group, Inc. (NASDAQ: XXII) reported results for the first quarter ended March 31, 2022.. The company will host a live audio webcast on May 5, at 10:00 a.m. ET. 
Via Benzinga
Investment Strategy Monthly Insights, April 2022
After four decades of low inflation, developed economies are grappling with an inflation spike. 
Via Talk Markets
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
Merck Projects $10 Billion From Its Next Blockbuster Segment; Will It Measure Up?
Merck shares hit a six-month high Tuesday on the bullish projection. 
Via Investor's Business Daily
What Stocks Do Well During a Bear Market? 7 Picks for a Downturn
These are the best bear market stocks to invest in now. T, BG and CL are some great picks for investors looking to weather the storm. 
Via InvestorPlace
Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia
Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines." 
Via Benzinga
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.